Table 1.
Study participant descriptive characteristics of demographics, cancer diagnosis, and cardiovascular risk factors.
| Control (No Cancer) Participants (n=236) | Cancer Pre-Treatment (n=37) | Cancer Survivors: Non-anthracycline Treatment (n=17) | Cancer Survivors: Anthracycline Treatment (n=37) | Group Difference p-value | |
|---|---|---|---|---|---|
| Age at exam, years | 67±9 | 56±15 | 57±12 | 53±13* | <0.0001 |
| Race/Ethnicity | 0.04 | ||||
| White | 149 (63) | 29 (78) | 15 (88) | 29 (78) | |
| Black | 86 (36) | 7 (19) | 2 (12) | 8 (22) | |
| Hispanic | 1 (<1) | 1 (3) | - | - | |
| Gender | <0.01 | ||||
| Female | 140 (59) | 25 (68) | 17 (100) | 29 (78)*,§ | |
| Male | 96 (41) | 12 (32) | - | 8 (22) | |
| Body mass index, kg/m2 | 28.6±5.2 | 28.3±5.5 | 28.8±7.6 | 29.2±6.0 | 0.92 |
| Cancer Type | - | ||||
| Breast | - | 13 (35) | 17 (100) | 21 (57) § | |
| Hematologic | - | 21 (57) | - | 16 (43) | |
| Sarcoma | - | 3 (8) | - | - | |
| CVD Risk Factors | |||||
| Known CAD | - | 2 (5) | 1 (6) | 2 (5)* | - |
| Diabetes | 38 (16) | 5 (14) | 2 (12) | 5 (14) | 0.93 |
| Hyperlipidemia | 19 (8) | 9 (24) | 4 (24) | 8 (22)* | <0.01 |
| Hypertension | 49 (21) | 13 (35) | 6 (35) | 13 (35) | 0.06 |
Measurements reported as frequency (percentage) or mean±standard deviation. CVD=cardiovascular disease; CAD=coronary artery disease. p<0.05 for anthracycline-treated survivors compared to*controls, †pre-treatment, and §non-anthracycline survivors.